Literature DB >> 8526696

The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation. Amiodarone vs quinidine for conversion of atrial fibrillation.

N Z Kerin1, K Faitel, M Naini.   

Abstract

BACKGROUND: Chronic atrial fibrillation (CAF) is a serious condition with significant morbidity and mortality. The mainstay of drug therapy for the conversion of atrial fibrillation to sinus rhythm continues to be quinidine. The value and safety of intravenously (i.v.) administered amiodarone therapy vs quinidine sulfate therapy was compared in a cohort of patients with CAF of more than 3 weeks' duration.
OBJECTIVES: To evaluate the efficacy of i.v. administered amiodarone and oral quinidine sulfate containing 300 mg of quinidine in the conversion of CAF and to assess the effect of oral amiodarone in the conversion of CAF in the patients in whom CAF did not convert with IV amiodarone.
METHODS: Thirty-two patients with CAF of more than 3 weeks' duration were randomized to either i.v. amiodarone treatment or oral digoxin/quinidine treatment in a randomized unblinded single crossover study. The converters continued either oral amiodarone therapy or quinidine extended-action tablet (Quinidex) therapy.
RESULTS: Seventeen patients were randomized to the quinidine group and 15 patients to the amiodarone group. Nonconverters from the quinidine group crossed over to the amiodarone group. Amiodarone and quinidine were equally effective at 24 hours in converting CAF (eight [47%] of 17 patients in the quinidine group vs 12 [44%] of 27 patients in the amiodarone group; P, not significant). At 2 and 9 months of oral therapy, amiodarone was superior to quinidine in maintaining sinus rhythm. Only two of eight patients in the quinidine group tolerated the medication. All patients in the amiodarone group tolerated the medication. One additional patient converted to sinus rhythm at 2 months (13 [48%] of 27), and five more patients converted at 9 months (18 [67%] of 27). Amiodarone therapy and digoxin/quinidine therapy were equally effective at 48 hours in controlling ventricular response at rest.
CONCLUSIONS: During the first 48 hours of treatment, i.v. amiodarone and oral quinidine were equally effective in converting CAF to sinus rhythm. At 2 and 9 months of therapy, treatment with oral amiodarone was superior to that of quinidine in restoring sinus rhythm. Long-term treatment with oral amiodarone is better tolerated than with quinidine.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8526696

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  9 in total

1.  Efficacy and safety of intravenous amiodarone in recent-onset atrial fibrillation: experience in patients admitted to a general internal medicine department.

Authors:  Y Kreiss; Y Sidi; H Gur
Journal:  Postgrad Med J       Date:  1999-05       Impact factor: 2.401

Review 2.  Atrial fibrillation: classification, pathophysiology, mechanisms and drug treatment.

Authors:  Vias Markides; Richard J Schilling
Journal:  Heart       Date:  2003-08       Impact factor: 5.994

3.  Acute conversion of persistent atrial fibrillation during dofetilide loading does not predict long-term atrial fibrillation-free survival.

Authors:  Shaan Khurshid; Simon Akerman; Jonathan P Man; Gregory Supple; Sanjay Dixit; Andrew E Epstein; Francis E Marchlinski; David S Frankel
Journal:  J Interv Card Electrophysiol       Date:  2015-01-27       Impact factor: 1.900

4.  Quinidine for Pharmacological Cardioversion of Long-lasting Atrial Fibrillation.

Authors:  Matteo Baroni; Antoine Kheir; Margherita Manfredi; Francesco Pattarino; Flavio Doni
Journal:  J Atr Fibrillation       Date:  2011-07-15

Review 5.  Pharmacological cardioversion of atrial fibrillation: current management and treatment options.

Authors:  Giuseppe Boriani; Igor Diemberger; Mauro Biffi; Cristian Martignani; Angelo Branzi
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 6.  Pharmacologic management of atrial fibrillation in the elderly: rate control, rhythm control, and anticoagulation.

Authors:  Seth McClennen; Peter J Zimetbaum
Journal:  Curr Cardiol Rep       Date:  2003-09       Impact factor: 2.931

Review 7.  [Pharmaceutical treatment of atrial fibrillation].

Authors:  Anil-Martin Sinha; Johannes Brachmann; Martin Schmidt
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2008-07-13

8.  Quinidine for pharmacological cardioversion of atrial fibrillation: a retrospective analysis in 501 consecutive patients.

Authors:  Bernhard Schwaab; Alexander Katalinic; Uta Maria Böge; Jürgen Loh; Peter Blank; Tatjana Kölzow; Dirk Poppe; Hendrik Bonnemeier
Journal:  Ann Noninvasive Electrocardiol       Date:  2009-04       Impact factor: 1.468

Review 9.  Clinical review: clinical management of atrial fibrillation - rate control versus rhythm control.

Authors:  Hoong Sern Lim; Ali Hamaad; Gregory Y H Lip
Journal:  Crit Care       Date:  2004-02-19       Impact factor: 9.097

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.